Novo Nordisk is Funding New Manufacturing Facility in Denmark

The H-Investments Team

Dec 17, 2024 — 1 min read

Novo Nordisk will establish a modular, adaptable production facility in Odense, Denmark

Novo Nordisk announced a $1.2 billion production plant in Odense, Denmark, on Dec. 16, 2024. The facility will house present and future hemophilia treatment products. In a press release, Novo Nordisk said this investment is its first in Denmark this century.

A modern finished production plant and storage will extend over 40,000 m2 at the new site. To make several rare disease-treating pharmaceuticals, the production plant will be modular and versatile.

"The facility will use advanced technology and innovative equipment to ensure patient quality and meet the growing global demand for our life-changing medicines," said Novo Nordisk executive vice-president, Product Supply, Quality & IT Henrik Wulff in a press release. “We are happy to build on our tradition in Denmark and look forward to starting this journey in Odense, a well-connected city with energetic community and bright team."

The new facility will try to preserve the local environment. Over 4000 trees will be planted, and buildings will have solar panels to generate electricity. In its announcement, the company said it would reuse leftover soil, timber, and other sustainable resources to construct public lakes, woods, and community areas.

Beginning construction, completion is planned in 2027. The facilities will provide around 400 permanent jobs and up to 1000 on-site positions for external workers.

Source: Novo Nordisk

Roche reports the Prasinezumab aids in early-stage Parkinson's

The main goal of the Phase IIb study wasn't met with statistically significant results, but there is still some good news On Dec. 18, 2024, Roche shared results from a Phase IIb study (PADOVA) where prasinezumab, an investigational monoclonal antibody (mAb), did not meet the study’s primary

Lilly and Amgen - Major Expansions of US Manufacturing Sites

Lilly will invest $3 billion in its newly purchased Wisconsin manufacturing site, and Amgen will invest $1 billion in North Carolina. Companies Amgen of Holly Springs, North Carolina, and Eli Lilly and Company (Lilly) of Kenosha County, Wisconsin, have each declared intentions to increase production capacity. Amgen has announced a

New Pharmaceutical Shortages Surveillance Platform in Europe

The new system for reporting medication shortages by holders of market authorizations is now active With the launch of its primary functions, the European Shortages Monitoring Platform (ESMP) was announced by the European Medicines Agency (EMA) on November 28, 2024. With the help of ESMP, MAHs can regularly report shortages

PTC Therapeutics' AADC Gene Therapy Receives FDA Approval

Eladocagene exuparvovec-tneq (Kebilidi) is the first FDA-approved gene therapy for AADC deficiency The FDA has approved eladocagene exuparvovec-tneq (Kebilidi, PTC Therapeutics), a gene therapy using an adeno-associated virus vector, for the treatment of both adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first gene

Read more

Roche reports the Prasinezumab aids in early-stage Parkinson's

Lilly and Amgen - Major Expansions of US Manufacturing Sites

New Pharmaceutical Shortages Surveillance Platform in Europe

PTC Therapeutics' AADC Gene Therapy Receives FDA Approval